The assessment discusses fifty eight peptides in various clinical phases, indicating a robust pipeline of peptide therapies concentrating on PPIs. Clinical trials and preclinical studies are highlighted, showing the efficacy of peptide vaccines in inducing an immune reaction, with the potential to boost survival charges for HCC individuals. P